Frontlight ResearchEarly access
TerminatedPhase 1/2
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Key facts
- Who runs it
- Helix BioPharma Corporation
- Where
- Milwaukee, Morristown, and Scottsdale, United StatesSee the 3 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 28 people enrolled
- Started
- 11 Dec 2019
- Ended
- 24 Oct 2024
- Type of study
- Interventional
- Treatments tested
- L-DOS47
- Doxorubicin
- Record updated
- 6 May 2025
- Why it stopped
- The primary reason for early termination was budget constraint.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (25)Hide the full registry criteria
Who can take part
- Male or female aged ≥ 18 years old
- One or more metastatic tumors measurable on computed tomography (CT) scan per RECIST version 1.1 and screening FDG-PET scan with maximum standardized uptake value (SUV max) ≥ 5.5 for at least one lesion consistent with pancreatic cancer
- Karnofsky performance status ≥ 70%
- Life expectancy of at least 3 months
- Able to understand the information provided to them and to give written institutional review board (IRB)-approved informed consent prior to any study activities being conducted
- A negative pregnancy test (if of child bearing potential)
- Acceptable liver function:; Bilirubin ≤ 1.5 times upper limit of normal; Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and Alkaline phosphatase (ALP) ≤ 2.5 times upper limit of normal (ULN; if liver metastases are present, then ≤ 5 x ULN is allowed)
- Acceptable renal function as defined by creatinine ≤1.5x institutional upper limits of normal, or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
- Acceptable hematologic status:; Granulocyte ≥ 1500 cells/mm3; Platelet count ≥ 100,000 (plt/mm3); Hemoglobin ≥ 9g/dL
- Urinalysis:; No clinically significant abnormalities
- Acceptable coagulation status; Prothrombin time within 1.5x of normal limits; Partial thromboplastin time (PTT) within 1.5x of normal limits
- For men and women of child-bearing potential, the use of effective contraceptive methods during the study
- Normal ejection fraction on ECHO or MUGA
Who cannot take part
- Pregnant or nursing women. NOTE: Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant while participating in this study, she should inform her treating physician immediately
- Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 3 weeks prior to study entry
- Major surgery within 4 weeks prior to study entry
- Patients who are currently receiving any other investigational agent
- New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG
- Active, uncontrolled bacterial, viral, or fungal infections requiring systematic therapy
- Known infection with HIV, hepatitis B, or hepatitis C
- Serious nonmalignant disease (eg hydro nephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor
- Abnormal ejection fraction on ECHO or MUGA
- Patients with marked screening prolongation of QT/QTc interval (e.g. repeated demonstration of a QTc interval > 480 milliseconds (CTCAE grade 1) using Fredericia's QT correction formula
- Unwillingness or inability to comply with procedures required in this protocol
- Patients with any evidence of uncontrolled brain metastases or carcinomatosis meningitis
Where in United States
- Froedtert Hospital and the Medical College of WisconsinMilwaukee, United States
- Atlantic Health System / Morristown Medical CenterMorristown, United States
- Scottsdale Healthcare Hospitals DBA HonorHealthScottsdale, United States
About the trial
What the trial wants to find out
This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.
The group in the trial
- L-DOS47 + doxorubicinTreatment being tested
Patients will be recruited into escalating dosing cohorts of 3, 6 and 9 µg/kg of L-DOS47, with a minimum of 3 and a maximum of 6 patients per cohort. A fixed dose of intravenous doxorubicin \[20 mg/m2/week\] will be administered in combination with L-DOS47 across all cohorts.
Treatment: L-DOS47 and Doxorubicin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients With Previously Treated Advanced Pancreatic Cancer
- Record updated
- 6 May 2025